Skip to content

Diagnosing Pulmonary Embolism in the Context of Common Alternative Diagnoses in primary care

Diagnosing Pulmonary Embolism in the Context of Common Alternative Diagnoses in primary care - PECAN study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON52757
Enrollment
750
Registered
2018-08-01
Start date
2018-11-01
Completion date
Unknown
Last updated
2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bloodclot in pulmonary artery Pulmonary embolism

Interventions

None listed

Sponsors

Universitair Medisch Centrum Utrecht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Subacute new onset or worsening of existing shortness of breath with or without chest symptoms, in whom the general practitioner first wants to exclude pulmonary embolism (PE); - Age >= 18 years.

Exclusion criteria

Exclusion criteria: - Pregnancy; - Already using anticoagulants (i.e. a vitamin K antagonist, low-molecular weight heparine or a direct oral anticoagulant); - Life expectancy

Design outcomes

Primary

MeasureTime frame
The primary outcomes of this study will be both the proportion false negatives (i.e. the proportion of missed PE cases with a negative YEARS-strategy) and the efficiency of the strategy (i.e. the total number of patients with a negative YEARS-strategy as a proportion of all suspected cases) in primary care.

Secondary

MeasureTime frame
The secondary endpoints are the alternative diagnosis besides PE after 3 months of follow-up, with most importantly pneumonia. With this endpoint and the information obtained from the POC-assay for CRP, we will quantify the diagnostic value of CRP by multivariable logistic regression analyses. Besides, factors associated with a positive score on the subjective YEARS-item *PE most likely* will be identified.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)